Genetic Testing and Precision Medicine
Cancers are genetic diseases caused by the gradual accumulation of mutations. When cell-regulating genes are mutated or damaged, cells lose control and proliferate endlessly, eventually leading to malignant tumors.
Accurate identification of each unique gene mutation in a patient’s solid tumor provides the best clinical evidence for precise clinical treatment, molecular classification and monitoring for residual disease and recurrence, as well as providing key information for new scientific discovery.
CanSelect™ Whole Exome Sequencing (WES)
Covering the whole human genome with a total of about 21,000 genes. CanSelect WES also conducts MSI analysis and genetic tests related to 29 chemotherapies. It is by far the most comprehensive genetic testing solution with the potential of accessing medicine under research and development. With an average sequencing depth of 200x, it ensures the accuracy of detection and over 95% coverage of the whole genome region.
· 21,000 genes mutation analysis
· Mutations in the signal pathways and functional analysis
· Matching of global approved targeted drugs or drugs in trials
· Prediction of PD1 and PD - L1 immunotherapy efficacy
· Guidance for 21 chemotherapy drugs
· Maximum detection – Covers the whole human genome with a total of about 21,000 genes, currently the most comprehensive sequencing product on the market.
· Maximum coverage – Matches all targeted cancer therapies on the market, more than 180 drugs under development, and more than 3,000 cancer drugs in clinical trials, to find the best treatment opportunities.
· Most comprehensive information – Provides in-depth gene-sequencing information for all kinds of common variants and low-frequency variants, yielding maximum discovery of disease pathogenesis.
· World-leading sequencing platform – Uses high-throughput and highly effective Illumina sequencing platform.
· Guaranteed data accuracy with two independent algorithms for data analysis – Provides comprehensive, rapid and accurate analysis of cancer mutations with two independent proprietary algorithms from John Hopkins University and Genetron Health.
· Professional report interpretation and follow-up – Provides one-on-one professional medical interpretation and consulting, with regular follow-up every three months, and report updates every six months with latest scientific findings.
All solid-tumor patients (newly diagnosed patient, patients with drug resistance and patients with disease relapse)
Tumor sample (one of the following)
Fresh tissue: surgery (mung bean size), biopsy (more than 2 pieces), formalin fixed tissue (1 piece of mung bean size)
Frozen tissue: surgery (mung bean size), biopsy (> 2 pieces)
Paraffin slides: surgery (over 5 slides), biopsy (15-20 slides)
Paraffin blocks: 1 piece (mung bean size)
5 ml peripheral blood, or 2 ml saliva, or 50 ml saliva mouthwash (choose one, peripheral blood preferred)
Turnaround time (TAT)
20 days (upon receiving samples)